Non-alcoholic Fatty Liver Disease: From Steatosis to Cirrhosis

Simple item page
dc.contributor.authorFarrell, Geoffrey
dc.contributor.authorLarter, Claire
dc.date.accessioned2015-12-10T22:39:46Z
dc.date.issued2006
dc.date.updated2015-12-09T10:54:16Z
dc.description.abstractNonalcoholic steatohepatitis (NASH), the lynchpin between steatosis and cirrhosis in the spectrum of nonalcoholic fatty liver disorders (NAFLD), was barely recognized in 1981. NAFLD is now present in 17% to 33% of Americans, has a worldwide distribution,
dc.identifier.issn0270-9139
dc.identifier.urihttp://hdl.handle.net/1885/57331
dc.publisherW B Saunders Co
dc.sourceHepatology
dc.subjectKeywords: alpha tocopherol; ascorbic acid; betaine; cytokine; glitazone derivative; metformin; pentoxifylline; peroxisome proliferator activated receptor alpha agonist; peroxisome proliferator activated receptor gamma agonist; pioglitazone; placebo; rosiglitazone;
dc.titleNon-alcoholic Fatty Liver Disease: From Steatosis to Cirrhosis
dc.typeJournal article
local.bibliographicCitation.issue2 (supp 1)
local.bibliographicCitation.lastpageS112
local.bibliographicCitation.startpageS99
local.contributor.affiliationFarrell, Geoffrey, College of Medicine, Biology and Environment, ANU
local.contributor.affiliationLarter, Claire, University of Sydney
local.contributor.authoruidFarrell, Geoffrey, u4028700
local.description.embargo2037-12-31
local.description.notesImported from ARIES
local.identifier.absfor110307 - Gastroenterology and Hepatology
local.identifier.ariespublicationu4167262xPUB396
local.identifier.citationvolume43
local.identifier.doi10.1002/hep.20973
local.identifier.scopusID2-s2.0-33644547706
local.type.statusPublished Version

Downloads

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
01_Farrell_Non-alcoholic_Fatty_Liver_2006.pdf
Size:
4.14 MB
Format:
Adobe Portable Document Format
Download

Collections

ANU Research Publications

DSpace software copyright © 2002-2026 LYRASIS